These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20380851)

  • 21. Younger age at vaccination may increase risk of varicella vaccine failure.
    Galil K; Fair E; Mountcastle N; Britz P; Seward J
    J Infect Dis; 2002 Jul; 186(1):102-5. PubMed ID: 12089668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A role for genetics in the immune response to the varicella vaccine.
    Klein NP; Fireman B; Enright A; Ray P; Black S; Dekker CL;
    Pediatr Infect Dis J; 2007 Apr; 26(4):300-5. PubMed ID: 17414391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005.
    Chaves SS; Zhang J; Civen R; Watson BM; Carbajal T; Perella D; Seward JF
    J Infect Dis; 2008 Mar; 197 Suppl 2():S127-31. PubMed ID: 18419385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Varicella vaccine effectiveness in the US vaccination program: a review.
    Seward JF; Marin M; Vázquez M
    J Infect Dis; 2008 Mar; 197 Suppl 2():S82-9. PubMed ID: 18419415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactogenicity and immunogenicity of a varicella vaccine in healthy seronegative and seropositive subjects.
    Barzaga NG; Florese RH; Bock HL
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):259-67. PubMed ID: 12236423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspective on live varicella vaccine.
    Gershon AA; Katz SL
    J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination of children with malignant disease against varicella.
    Slørdahl SH; Wiger D; Strømøy T; Degre M; Thørsby E; Lie SO
    Postgrad Med J; 1985; 61 Suppl 4():85-92. PubMed ID: 3014484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety and efficacy of varicella vaccine in healthy children--one year follow-up].
    Jackowska T; Dziadek J; Wasilewski R; Wasik M
    Med Wieku Rozwoj; 2008; 12(2 Pt 2):653-9. PubMed ID: 19418940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of varicella-zoster virus in Polish population.
    Siennicka J; Trzcińska A; Rosińska M; Litwińska B
    Przegl Epidemiol; 2009; 63(4):495-9. PubMed ID: 20120946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Live attenuated varicella vaccine in healthy 12- to 24-month-old children.
    Johnson CE; Shurin PA; Fattlar D; Rome LP; Kumar ML
    Pediatrics; 1988 Apr; 81(4):512-8. PubMed ID: 2832819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of varicella hospitalizations in the United States, 1995-2005.
    Reynolds MA; Watson BM; Plott-Adams KK; Jumaan AO; Galil K; Maupin TJ; Zhang JX; Seward JF
    J Infect Dis; 2008 Mar; 197 Suppl 2():S120-6. PubMed ID: 18419384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Varicella rates among unvaccinated and one-dose vaccinated healthy children in Izmir, Turkey.
    Kurugol Z; Halicioglu O; Koc F; Koturoglu G; Aksit S
    Int J Infect Dis; 2011 Jul; 15(7):e475-80. PubMed ID: 21592838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines.
    Cohen DI; Davidovici BB; Smetana Z; Balicer RD; Klement E; Mendelson E; Green MS
    Infection; 2006 Aug; 34(4):208-13. PubMed ID: 16896579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine.
    Asano Y; Nagai T; Miyata T; Yazaki T; Ito S; Yamanishi K; Takahashi M
    Pediatrics; 1985 Apr; 75(4):667-71. PubMed ID: 2984636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative varicella vaccine effectiveness during outbreaks in day-care centres.
    Spackova M; Wiese-Posselt M; Dehnert M; Matysiak-Klose D; Heininger U; Siedler A
    Vaccine; 2010 Jan; 28(3):686-91. PubMed ID: 19874924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Varicella vaccination in Japan, South Korea, and Europe.
    Sadzot-Delvaux C; Rentier B; Wutzler P; Asano Y; Suga S; Yoshikawa T; Plotkin SA
    J Infect Dis; 2008 Mar; 197 Suppl 2():S185-90. PubMed ID: 18419395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Varicella vaccine].
    Abarca Villaseca K
    Rev Chilena Infectol; 2006 Mar; 23(1):56-9. PubMed ID: 16462966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effectiveness of varicella vaccine in China.
    Fu C; Wang M; Liang J; Xu J; Wang C; Bialek S
    Pediatr Infect Dis J; 2010 Aug; 29(8):690-3. PubMed ID: 20216242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.